• Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

    Источник: Nasdaq GlobeNewswire / 13 мар 2024 16:05:00   America/New_York

    RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.

    Thursday, March 21st @ 8:30 a.m. ET 
    Domestic:1-888-886-7786
    International:1-416-764-8658
    Conference ID:27947513
    Webcast:Link
      

    Participants can use the dial-in information above or choose the Call me™ option (click here) for instant telephone access to the event which will be made active 15 minutes prior to the scheduled start time. A live webcast or replay of the conference call may be found here or on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

    About Mineralys Therapeutics
    Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com.

    Contact:
    Investor Relations
    investorrelations@mineralystx.com

    Media Relations
    Tom Weible
    Elixir Health Public Relations
    Phone: (1) 515-707-9678
    Email: tweible@elixirhealthpr.com


    Primary Logo

Опубликовать